In Papua New Guinea, 1500+ women die every year from childbirth-related causes – 80 times higher than in Australia. And these deaths are, mostly, preventable.
Your support will help stop preventable deaths of mothers and babies in PNG
Harm Reduction - Australia
Harm reduction programs supported by government can be highly effective at stopping the transmission of hep C and HIV.
Prevention
A preventative vaccine will be essential for a global hepatitis C elimination program.
Testing
New diagnostics and greater awareness about testing is needed.
Treatment
Direct acting antiviral drugs are being tested in the TAP Study
Harm Reduction - Myanmar
Reducing the burden of hep C in Myanmar will be a focus of a new collaboration
Diagnostics development
Point-of-care alanine aminotransferase (ALT) diagnostic development
The Prime Study
A randomised study comparing hepatitis C treatment in a primary care service with a hospital setting.
Research
Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected people.
Eliminating hepatitis C virus (HCV) in Australia is now a possibility, with the listing of direct-acting antiviral (DAA) drugs on the PBS. But this is one step in the path towards elimination.
Burnet will also make a major contribution in global efforts to eliminate hepatitis B & C as major health threats. This includes supporting vital research underway by our researchers to create a novel, effective, low-cost HCV vaccine suitable for resource-constrained countries.
Burnet Institute’s Eliminate Viral Hepatitis strategy is focussed on:
Working together, with research organisations, governments, the community and affected populations, Burnet will help change the course of hepatitis C infection and its impact as a public health threat.
Hepatitis C virus (HCV) affects more than 250,000 Australians resulting in up to 630 deaths from liver cancer and liver failure each year. Globally, more than 500,000 people die from HCV-related causes.
The ambitious journey to eliminate viral hepatitis has begun.
Deputy Director (Programs); Adjunct Professor, Monash University, DEPM.
+61385062304
A universal prophylactic vaccine against HCV
Protection against seven circulating genotypes will be essential to the success of an HCV vaccine.
ACCESS: STI and BBV surveillance system
ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.
ALT point-of-care diagnostic to detect liver disease
Nanjing BioPoint is developing a new diagnostic for detecting liver disease.
ATAHC 2: Australian Trial in Acute Hepatitis C II
The ATAHC 2 study will examine the effect of interferon with or without Ribavirin in recent HCV infection.
B cell response to HCV infection
This research will inform vaccine design to favour the elicitation of protective antibody specificities.
co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.
DAA based therapy for recently acquired hepatitis C – II (DARE-C II)
To evaluate the combination of SOF plus RBV in patients with recently acquired HCV infection.
DARE C: ATAHC II Substudy
DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
EC Partnership: Eliminate Hepatitis C Partnership
Informing the elimination of HCV through a community-based nurse-led model of care and treatment.
HCV Elimination Modelling
Providing evidence-based policy recommendations for prevention, testing and treatment of Hepatitis C.
Methods for improved sensitivity of lateral flow tests
Integrating innovative techniques in nanotechnology to the development of robust and sensitive rapid assays.
Rapid-EC hepatitis C Pilot Study
Investigating the feasibility of providing rapid point-of-care testing for hepatitis C in community clinics.
SHARP: Screening for Hepatitis in At-Risk Populations
A collaborative project between Burnet Institute and Cancer Council Victoria.
TAP: Treatment and Prevention Hep C study
Does treating people who inject drugs for their hep C reduce transmission and prevalence?
The Prime Study: Treating hep C in primary healthcare setting
Examining feasibility of treating people with genotype 1 hepatitis C in primary healthcare setting.
05 February, 2018
Burnet’s Professor Margaret Hellard to chair the viral hepatitis forum featuring global experts.
01 February, 2018
Important Burnet Institute studies have attracted funding from the Australian Centre for HIV and Hepatitis Virology Research.
30 July, 2018
Join the discussion about how we can eliminate viral hepatitis.
13 November, 2018
Professor Margaret Hellard will chair the viral hepatitis forum at the World Innovation Summit for Health (WISH) in Qatar.
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Disclaimer Privacy Policy Complaints Policy
Copyright © 2018 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
